Top Tweets for #CellTx

Razan Mohty @Razan_Mohty

7 months ago

So humbling to see pioneers in the #cellTx field being honored. A treatment that shaped the field and changed the outcomes for patients all over the world. #ASH25

Jordan Gauthier

7 months ago

Cell therapy legend Prof. Rainer Storb, recipient of the Wallace H. Coulter Award, prefacing the #ASH25 Plenary Session in front of a packed room. 🙌 @fredhutch #fanboy

2

90

21

2

10K

0

23

1

1

3K

Krish Patel @KrishPatelMD

11 months ago

Fabulous talk on challenges and opportunities in trials for Cell Tx in GI Malignancies from @MeredithPelster @SarahCannonDocs #CellTx #GIOnc #SeattleCT25

KrishPatelMD's tweet photo. Fabulous talk on challenges and opportunities in trials for Cell Tx in GI Malignancies from @MeredithPelster @SarahCannonDocs #CellTx #GIOnc #SeattleCT25 https://t.co/w7oN7vSBMb

1

19

2

1

1K

Chimerically Speaking @ChimeraSpeaking

almost 2 years ago

Don't miss our conversation with @adamkittai about #celltx and #bmtsm for #lymsm CLL and Richter's Transformation! Conversation jam-packed with clinical and career wisdom.

0

3

1

0

325

Chimerically Speaking @ChimeraSpeaking

almost 2 years ago

Season 2 is live! So excited to share our conversation with @AdamKittai @TischCancer about #bmtsm and #celltx in CLL and Richter’s transformation. We discussed CAR for RT and the recent liso-cel approval in CLL, and more! https://t.co/BnRudkoIO6

0

7

2

0

2K

Aaron Logan, MD, PhD, MPhil @hemedoc

over 2 years ago

#ASH23 #leusm #celltx Kopmar: ROCCA has 25 centers contributing. N=152 reported here. 31% Ph+. Median age 46. CRS 82% all gr, 9% gr 3+. ICANS 56% all gr, 31% gr 3+. Real world mgmt of CRS better than ZUMA3, but ICANS still a significant issue.

hemedoc's tweet photo. #ASH23 #leusm #celltx Kopmar: ROCCA has 25 centers contributing. N=152 reported here. 31% Ph+. Median age 46. CRS 82% all gr, 9% gr 3+. ICANS 56% all gr, 31% gr 3+. Real world mgmt of CRS better than ZUMA3, but ICANS still a significant issue. https://t.co/Kp3owXrtPA

hemedoc's tweet photo. #ASH23 #leusm #celltx Kopmar: ROCCA has 25 centers contributing. N=152 reported here. 31% Ph+. Median age 46. CRS 82% all gr, 9% gr 3+. ICANS 56% all gr, 31% gr 3+. Real world mgmt of CRS better than ZUMA3, but ICANS still a significant issue. https://t.co/Kp3owXrtPA

hemedoc's tweet photo. #ASH23 #leusm #celltx Kopmar: ROCCA has 25 centers contributing. N=152 reported here. 31% Ph+. Median age 46. CRS 82% all gr, 9% gr 3+. ICANS 56% all gr, 31% gr 3+. Real world mgmt of CRS better than ZUMA3, but ICANS still a significant issue. https://t.co/Kp3owXrtPA

hemedoc's tweet photo. #ASH23 #leusm #celltx Kopmar: ROCCA has 25 centers contributing. N=152 reported here. 31% Ph+. Median age 46. CRS 82% all gr, 9% gr 3+. ICANS 56% all gr, 31% gr 3+. Real world mgmt of CRS better than ZUMA3, but ICANS still a significant issue. https://t.co/Kp3owXrtPA

2

9

4

1

1K

Aaron Logan, MD, PhD, MPhil @hemedoc

over 2 years ago

#ASH23 #leusm #celltx Roddie: median EFS 11.7mos. Bridging therapy still needs to be optimized. Some have increased, some decreased dz burden prior to infusion.

hemedoc's tweet photo. #ASH23 #leusm #celltx Roddie: median EFS 11.7mos. Bridging therapy still needs to be optimized. Some have increased, some decreased dz burden prior to infusion. https://t.co/N7LCkrfDpy

hemedoc's tweet photo. #ASH23 #leusm #celltx Roddie: median EFS 11.7mos. Bridging therapy still needs to be optimized. Some have increased, some decreased dz burden prior to infusion. https://t.co/N7LCkrfDpy

hemedoc's tweet photo. #ASH23 #leusm #celltx Roddie: median EFS 11.7mos. Bridging therapy still needs to be optimized. Some have increased, some decreased dz burden prior to infusion. https://t.co/N7LCkrfDpy

hemedoc's tweet photo. #ASH23 #leusm #celltx Roddie: median EFS 11.7mos. Bridging therapy still needs to be optimized. Some have increased, some decreased dz burden prior to infusion. https://t.co/N7LCkrfDpy

0

3

3

2

667

Aaron Logan, MD, PhD, MPhil @hemedoc

over 2 years ago

#ASH23 #leusm #celltx Roddie: Obe-cel for RR B-ALL (FELIX study). Fast off rate CD19 binder with 41BB costim. Split doses based on leukemia burden to help minimize toxicity (total dose across 2 doses 410M CART for all). This study has refractory, MRD and isolated EMD cohorts.

$hemedoc's tweet photo. #ASH23 #leusm #celltx Roddie: Obe-cel for RR B-ALL (FELIX study). Fast off rate CD19 binder with 41BB costim. Split doses based on leukemia burden to help minimize toxicity (total dose across 2 doses 410M CART for all). This study has refractory, MRD and isolated EMD cohorts. https://t.co/4SzHfD4KA3$

$hemedoc's tweet photo. #ASH23 #leusm #celltx Roddie: Obe-cel for RR B-ALL (FELIX study). Fast off rate CD19 binder with 41BB costim. Split doses based on leukemia burden to help minimize toxicity (total dose across 2 doses 410M CART for all). This study has refractory, MRD and isolated EMD cohorts. https://t.co/4SzHfD4KA3$

$hemedoc's tweet photo. #ASH23 #leusm #celltx Roddie: Obe-cel for RR B-ALL (FELIX study). Fast off rate CD19 binder with 41BB costim. Split doses based on leukemia burden to help minimize toxicity (total dose across 2 doses 410M CART for all). This study has refractory, MRD and isolated EMD cohorts. https://t.co/4SzHfD4KA3$

$hemedoc's tweet photo. #ASH23 #leusm #celltx Roddie: Obe-cel for RR B-ALL (FELIX study). Fast off rate CD19 binder with 41BB costim. Split doses based on leukemia burden to help minimize toxicity (total dose across 2 doses 410M CART for all). This study has refractory, MRD and isolated EMD cohorts. https://t.co/4SzHfD4KA3$

0

4

2

2

498

Aaron Logan, MD, PhD, MPhil @hemedoc

over 2 years ago

#ASH23 #leusm #celltx Roddie: best outcomes (>80% durable CR so far) in those w <5% blasts at start of LD. In those w 5-75% blasts, ~50% sustained CR (median duration 15mos). Very, very low rates of CRS and ICANS with incidence correlated to dz burden. Amenable to outpt inf=🔑.

hemedoc's tweet photo. #ASH23 #leusm #celltx Roddie: best outcomes (>80% durable CR so far) in those w <5% blasts at start of LD. In those w 5-75% blasts, ~50% sustained CR (median duration 15mos). Very, very low rates of CRS and ICANS with incidence correlated to dz burden. Amenable to outpt inf=🔑. https://t.co/CVB8DLR23s

hemedoc's tweet photo. #ASH23 #leusm #celltx Roddie: best outcomes (>80% durable CR so far) in those w <5% blasts at start of LD. In those w 5-75% blasts, ~50% sustained CR (median duration 15mos). Very, very low rates of CRS and ICANS with incidence correlated to dz burden. Amenable to outpt inf=🔑. https://t.co/CVB8DLR23s

hemedoc's tweet photo. #ASH23 #leusm #celltx Roddie: best outcomes (>80% durable CR so far) in those w <5% blasts at start of LD. In those w 5-75% blasts, ~50% sustained CR (median duration 15mos). Very, very low rates of CRS and ICANS with incidence correlated to dz burden. Amenable to outpt inf=🔑. https://t.co/CVB8DLR23s

hemedoc's tweet photo. #ASH23 #leusm #celltx Roddie: best outcomes (>80% durable CR so far) in those w <5% blasts at start of LD. In those w 5-75% blasts, ~50% sustained CR (median duration 15mos). Very, very low rates of CRS and ICANS with incidence correlated to dz burden. Amenable to outpt inf=🔑. https://t.co/CVB8DLR23s

1

24

7

3

4K

Aaron Logan, MD, PhD, MPhil @hemedoc

over 2 years ago

#ASH23 #leusm #celltx Roddie: 83% of enrolled were infused. Prior allo (44%), blin (42%), ino (31%). Vein to release 22 days. 74% CR/CRi in morphological dz cohorts, 100% MRD neg in low burden cohorts.

hemedoc's tweet photo. #ASH23 #leusm #celltx Roddie: 83% of enrolled were infused. Prior allo (44%), blin (42%), ino (31%). Vein to release 22 days. 74% CR/CRi in morphological dz cohorts, 100% MRD neg in low burden cohorts. https://t.co/hCd82dUTf9

hemedoc's tweet photo. #ASH23 #leusm #celltx Roddie: 83% of enrolled were infused. Prior allo (44%), blin (42%), ino (31%). Vein to release 22 days. 74% CR/CRi in morphological dz cohorts, 100% MRD neg in low burden cohorts. https://t.co/hCd82dUTf9

hemedoc's tweet photo. #ASH23 #leusm #celltx Roddie: 83% of enrolled were infused. Prior allo (44%), blin (42%), ino (31%). Vein to release 22 days. 74% CR/CRi in morphological dz cohorts, 100% MRD neg in low burden cohorts. https://t.co/hCd82dUTf9

hemedoc's tweet photo. #ASH23 #leusm #celltx Roddie: 83% of enrolled were infused. Prior allo (44%), blin (42%), ino (31%). Vein to release 22 days. 74% CR/CRi in morphological dz cohorts, 100% MRD neg in low burden cohorts. https://t.co/hCd82dUTf9

0

5

3

2

780

Aaron Logan, MD, PhD, MPhil @hemedoc

over 2 years ago

#ASH23 #lymsm #celltx Budde: BAFFR CART are polyfunctional (CD4 and CD8 with mix of effector, stimulator, etc , cell types). Nice evaluation of just 3 patients, but hard to know how broadly successful this could be as yet…

hemedoc's tweet photo. #ASH23 #lymsm #celltx Budde: BAFFR CART are polyfunctional (CD4 and CD8 with mix of effector, stimulator, etc , cell types). Nice evaluation of just 3 patients, but hard to know how broadly successful this could be as yet… https://t.co/VtBrkeeaVB

hemedoc's tweet photo. #ASH23 #lymsm #celltx Budde: BAFFR CART are polyfunctional (CD4 and CD8 with mix of effector, stimulator, etc , cell types). Nice evaluation of just 3 patients, but hard to know how broadly successful this could be as yet… https://t.co/VtBrkeeaVB

hemedoc's tweet photo. #ASH23 #lymsm #celltx Budde: BAFFR CART are polyfunctional (CD4 and CD8 with mix of effector, stimulator, etc , cell types). Nice evaluation of just 3 patients, but hard to know how broadly successful this could be as yet… https://t.co/VtBrkeeaVB

0

2

2

1

433

Aaron Logan, MD, PhD, MPhil @hemedoc

over 2 years ago

#ASH23 #lymsm #celltx Budde: BAFFR targeted CART in lymphoma. High expression of BAFFR on MCL, MZL, CLL and 50% LBCL. BAFFR loss unlikely because essential doe B cell development.

hemedoc's tweet photo. #ASH23 #lymsm #celltx Budde: BAFFR targeted CART in lymphoma. High expression of BAFFR on MCL, MZL, CLL and 50% LBCL. BAFFR loss unlikely because essential doe B cell development. https://t.co/6giGSBWWnS

hemedoc's tweet photo. #ASH23 #lymsm #celltx Budde: BAFFR targeted CART in lymphoma. High expression of BAFFR on MCL, MZL, CLL and 50% LBCL. BAFFR loss unlikely because essential doe B cell development. https://t.co/6giGSBWWnS

hemedoc's tweet photo. #ASH23 #lymsm #celltx Budde: BAFFR targeted CART in lymphoma. High expression of BAFFR on MCL, MZL, CLL and 50% LBCL. BAFFR loss unlikely because essential doe B cell development. https://t.co/6giGSBWWnS

0

2

1

2

559

Aaron Logan, MD, PhD, MPhil @hemedoc

over 2 years ago

#ASH23 #celltx Mueller: responses seen in all dz types. B cell recovery day 60+ wo flare of dz.

hemedoc's tweet photo. #ASH23 #celltx Mueller: responses seen in all dz types. B cell recovery day 60+ wo flare of dz. https://t.co/ApW14yFT53

hemedoc's tweet photo. #ASH23 #celltx Mueller: responses seen in all dz types. B cell recovery day 60+ wo flare of dz. https://t.co/ApW14yFT53

hemedoc's tweet photo. #ASH23 #celltx Mueller: responses seen in all dz types. B cell recovery day 60+ wo flare of dz. https://t.co/ApW14yFT53

hemedoc's tweet photo. #ASH23 #celltx Mueller: responses seen in all dz types. B cell recovery day 60+ wo flare of dz. https://t.co/ApW14yFT53

0

2

2

2

365

Aaron Logan, MD, PhD, MPhil @hemedoc

over 2 years ago

#ASH23 #celltx Mueller: SLE, SSc, and autoimmune myositis eligible for this study with an FMC63/41BB construct. Little CRS (no gr3+ and only 1/15 gr2). 1/15 gr1 ICANS, none higher.

hemedoc's tweet photo. #ASH23 #celltx Mueller: SLE, SSc, and autoimmune myositis eligible for this study with an FMC63/41BB construct. Little CRS (no gr3+ and only 1/15 gr2). 1/15 gr1 ICANS, none higher. https://t.co/yhMIi9qP51

hemedoc's tweet photo. #ASH23 #celltx Mueller: SLE, SSc, and autoimmune myositis eligible for this study with an FMC63/41BB construct. Little CRS (no gr3+ and only 1/15 gr2). 1/15 gr1 ICANS, none higher. https://t.co/yhMIi9qP51

hemedoc's tweet photo. #ASH23 #celltx Mueller: SLE, SSc, and autoimmune myositis eligible for this study with an FMC63/41BB construct. Little CRS (no gr3+ and only 1/15 gr2). 1/15 gr1 ICANS, none higher. https://t.co/yhMIi9qP51

hemedoc's tweet photo. #ASH23 #celltx Mueller: SLE, SSc, and autoimmune myositis eligible for this study with an FMC63/41BB construct. Little CRS (no gr3+ and only 1/15 gr2). 1/15 gr1 ICANS, none higher. https://t.co/yhMIi9qP51

0

7

2

2

2K

Aaron Logan, MD, PhD, MPhil @hemedoc

over 2 years ago

#ASH23 #celltx Mueller: CD19 CART for autoimmune dz. CD19 attractive (vs CD20 or BCMA) because of broader and deeper depletion of B cells producing autoantibodies.

hemedoc's tweet photo. #ASH23 #celltx Mueller: CD19 CART for autoimmune dz. CD19 attractive (vs CD20 or BCMA) because of broader and deeper depletion of B cells producing autoantibodies. https://t.co/c73CEbIlFX

hemedoc's tweet photo. #ASH23 #celltx Mueller: CD19 CART for autoimmune dz. CD19 attractive (vs CD20 or BCMA) because of broader and deeper depletion of B cells producing autoantibodies. https://t.co/c73CEbIlFX

hemedoc's tweet photo. #ASH23 #celltx Mueller: CD19 CART for autoimmune dz. CD19 attractive (vs CD20 or BCMA) because of broader and deeper depletion of B cells producing autoantibodies. https://t.co/c73CEbIlFX

hemedoc's tweet photo. #ASH23 #celltx Mueller: CD19 CART for autoimmune dz. CD19 attractive (vs CD20 or BCMA) because of broader and deeper depletion of B cells producing autoantibodies. https://t.co/c73CEbIlFX

0

6

2

2

492

Aaron Logan, MD, PhD, MPhil @hemedoc

over 2 years ago

#ASH23 #mmsm #celltx Bal: ICANS 3.8% overall. ORR 91% at 150M dose, including uniform response in prior BCMA treated.

hemedoc's tweet photo. #ASH23 #mmsm #celltx Bal: ICANS 3.8% overall. ORR 91% at 150M dose, including uniform response in prior BCMA treated. https://t.co/BwndXYjrfJ

hemedoc's tweet photo. #ASH23 #mmsm #celltx Bal: ICANS 3.8% overall. ORR 91% at 150M dose, including uniform response in prior BCMA treated. https://t.co/BwndXYjrfJ

hemedoc's tweet photo. #ASH23 #mmsm #celltx Bal: ICANS 3.8% overall. ORR 91% at 150M dose, including uniform response in prior BCMA treated. https://t.co/BwndXYjrfJ

hemedoc's tweet photo. #ASH23 #mmsm #celltx Bal: ICANS 3.8% overall. ORR 91% at 150M dose, including uniform response in prior BCMA treated. https://t.co/BwndXYjrfJ

0

2

1

1

195

Aaron Logan, MD, PhD, MPhil @hemedoc

over 2 years ago

#ASH23 #mmsm #celltx Bal: GPRC5D-targeted BMS-986393 CART in RRMM, phase 1 data. Doses escalation identified RP2D 150M cells. N=84 overall, 26 at 150M. 88.5% CRS overall at 150M, none gr3+. Lots of cytopenias and infxns in 35%, 11.5% gr3+.

hemedoc's tweet photo. #ASH23 #mmsm #celltx Bal: GPRC5D-targeted BMS-986393 CART in RRMM, phase 1 data. Doses escalation identified RP2D 150M cells. N=84 overall, 26 at 150M. 88.5% CRS overall at 150M, none gr3+. Lots of cytopenias and infxns in 35%, 11.5% gr3+. https://t.co/1j8eqzVket

hemedoc's tweet photo. #ASH23 #mmsm #celltx Bal: GPRC5D-targeted BMS-986393 CART in RRMM, phase 1 data. Doses escalation identified RP2D 150M cells. N=84 overall, 26 at 150M. 88.5% CRS overall at 150M, none gr3+. Lots of cytopenias and infxns in 35%, 11.5% gr3+. https://t.co/1j8eqzVket

hemedoc's tweet photo. #ASH23 #mmsm #celltx Bal: GPRC5D-targeted BMS-986393 CART in RRMM, phase 1 data. Doses escalation identified RP2D 150M cells. N=84 overall, 26 at 150M. 88.5% CRS overall at 150M, none gr3+. Lots of cytopenias and infxns in 35%, 11.5% gr3+. https://t.co/1j8eqzVket

hemedoc's tweet photo. #ASH23 #mmsm #celltx Bal: GPRC5D-targeted BMS-986393 CART in RRMM, phase 1 data. Doses escalation identified RP2D 150M cells. N=84 overall, 26 at 150M. 88.5% CRS overall at 150M, none gr3+. Lots of cytopenias and infxns in 35%, 11.5% gr3+. https://t.co/1j8eqzVket

0

4

2

2

986

Aaron Logan, MD, PhD, MPhil @hemedoc

over 2 years ago

#ASH23 #leusm #celltx Lu: looks promising but not a destination therapy due to CD7 neg relapse. Need allo/2nd allo afterward. And will only be potentially useful for the <1/3 AML that express CD7. (NB: They have a rather large team!)

hemedoc's tweet photo. #ASH23 #leusm #celltx Lu: looks promising but not a destination therapy due to CD7 neg relapse. Need allo/2nd allo afterward. And will only be potentially useful for the <1/3 AML that express CD7.

(NB: They have a rather large team!) https://t.co/7odFAHpRDN

hemedoc's tweet photo. #ASH23 #leusm #celltx Lu: looks promising but not a destination therapy due to CD7 neg relapse. Need allo/2nd allo afterward. And will only be potentially useful for the <1/3 AML that express CD7.

(NB: They have a rather large team!) https://t.co/7odFAHpRDN

hemedoc's tweet photo. #ASH23 #leusm #celltx Lu: looks promising but not a destination therapy due to CD7 neg relapse. Need allo/2nd allo afterward. And will only be potentially useful for the <1/3 AML that express CD7.

(NB: They have a rather large team!) https://t.co/7odFAHpRDN

0

2

1

2

237

Aaron Logan, MD, PhD, MPhil @hemedoc

over 2 years ago

#ASH23 #leusm #celltx Lu: 70% CR/CRi after NS7. Median followup 6mos. CRS gr3 in 20%, gr1-2 in 80%. In some patients a CD7neg close emerged after clearance of dominant CD7+ clone.

hemedoc's tweet photo. #ASH23 #leusm #celltx Lu: 70% CR/CRi after NS7. Median followup 6mos. CRS gr3 in 20%, gr1-2 in 80%. In some patients a CD7neg close emerged after clearance of dominant CD7+ clone. https://t.co/cYAIpes1aE

hemedoc's tweet photo. #ASH23 #leusm #celltx Lu: 70% CR/CRi after NS7. Median followup 6mos. CRS gr3 in 20%, gr1-2 in 80%. In some patients a CD7neg close emerged after clearance of dominant CD7+ clone. https://t.co/cYAIpes1aE

hemedoc's tweet photo. #ASH23 #leusm #celltx Lu: 70% CR/CRi after NS7. Median followup 6mos. CRS gr3 in 20%, gr1-2 in 80%. In some patients a CD7neg close emerged after clearance of dominant CD7+ clone. https://t.co/cYAIpes1aE

hemedoc's tweet photo. #ASH23 #leusm #celltx Lu: 70% CR/CRi after NS7. Median followup 6mos. CRS gr3 in 20%, gr1-2 in 80%. In some patients a CD7neg close emerged after clearance of dominant CD7+ clone. https://t.co/cYAIpes1aE

0

4

2

1

478

Aaron Logan, MD, PhD, MPhil @hemedoc

over 2 years ago

#ASH23 #leusm #celltx Lu: CD7-targeted, fratricide resistant CART (NS7) in AML. ~12-32% of AML express CD7. 41BB costim. >50% CD7 required. N=10 so far. 70% post-allo relapse. Single dose.

hemedoc's tweet photo. #ASH23 #leusm #celltx Lu: CD7-targeted, fratricide resistant CART (NS7) in AML. ~12-32% of AML express CD7. 41BB costim. >50% CD7 required. N=10 so far. 70% post-allo relapse. Single dose. https://t.co/E31NWetJp6

hemedoc's tweet photo. #ASH23 #leusm #celltx Lu: CD7-targeted, fratricide resistant CART (NS7) in AML. ~12-32% of AML express CD7. 41BB costim. >50% CD7 required. N=10 so far. 70% post-allo relapse. Single dose. https://t.co/E31NWetJp6

hemedoc's tweet photo. #ASH23 #leusm #celltx Lu: CD7-targeted, fratricide resistant CART (NS7) in AML. ~12-32% of AML express CD7. 41BB costim. >50% CD7 required. N=10 so far. 70% post-allo relapse. Single dose. https://t.co/E31NWetJp6

hemedoc's tweet photo. #ASH23 #leusm #celltx Lu: CD7-targeted, fratricide resistant CART (NS7) in AML. ~12-32% of AML express CD7. 41BB costim. >50% CD7 required. N=10 so far. 70% post-allo relapse. Single dose. https://t.co/E31NWetJp6

0

8

3

1

2K

Aaron Logan, MD, PhD, MPhil @hemedoc

over 2 years ago

#ASH23 #leusm #celltx Bhagwat: increased pSTAT5 in AML cells during course of CART response. Ruxolitinib can abrogate protective effect of the myeloid cytokine mediated signaling that increases resistance to apoptosis in AML blasts.

hemedoc's tweet photo. #ASH23 #leusm #celltx Bhagwat: increased pSTAT5 in AML cells during course of CART response. Ruxolitinib can abrogate protective effect of the myeloid cytokine mediated signaling that increases resistance to apoptosis in AML blasts. https://t.co/EFjuL33Mk4

hemedoc's tweet photo. #ASH23 #leusm #celltx Bhagwat: increased pSTAT5 in AML cells during course of CART response. Ruxolitinib can abrogate protective effect of the myeloid cytokine mediated signaling that increases resistance to apoptosis in AML blasts. https://t.co/EFjuL33Mk4

hemedoc's tweet photo. #ASH23 #leusm #celltx Bhagwat: increased pSTAT5 in AML cells during course of CART response. Ruxolitinib can abrogate protective effect of the myeloid cytokine mediated signaling that increases resistance to apoptosis in AML blasts. https://t.co/EFjuL33Mk4

hemedoc's tweet photo. #ASH23 #leusm #celltx Bhagwat: increased pSTAT5 in AML cells during course of CART response. Ruxolitinib can abrogate protective effect of the myeloid cytokine mediated signaling that increases resistance to apoptosis in AML blasts. https://t.co/EFjuL33Mk4

0

3

2

2

343

Last Seen Hashtags on Sotwe

Trends for you

Most Popular Users